South Africa's competition watchdog probes Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market South Africa’s competition watchdog is investigating ...

Sanofi licensed the antibody from Alopexx Pharmaceuticals, a precursor to the current biotech of the same name, in 2009 but faced challenges such as the slow enrollment (PDF) of a phase 2a trial.

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that provide a clearer look at how the Teva-partnered prospect compares to Merck ...

Wall Street losses accelerated on Friday, with investors closing out the week with gloomy economic updates and report of a government investigation into UnitedHealth (UNH) in hand. However, the S ...

However, the trial retains high statistical power for analysis of efficacy endpoints since the data from the placebo patients from all concurrently enrolled sub-protocols (e.g. Sanofi and Boehringer ...